Vardeny O, et al. - In the PARADIGM-HF trial, researchers evaluated variations in diuretic dose requirements in patients treated with sacubitril/valsartan vs enalapril. Sacubitril/valsartan 200 mg BID or enalapril 10 mg BID were randomly administered to 8,399 patients with New York Heart Association class II–IV heart failure and reduced LVEF. At baseline and 6, 12, and 24 months, loop diuretic doses were evaluated. They calculated furosemide dose equivalents via multiplication factors (2x for torsemide and 40x for bumetanide). They noted that more loop diuretic dose reductions and fewer dose increases were evident in association with treatment with sacubitril/valsartan vs enalapril. According to findings, the requirement for loop diuretics could be attenuated with sacubitril/valsartan treatment vs enalapril in patients with heart failure with reduced ejection fraction.